HUHakan Uzunoglu

Hakan Uzunoglu

*This is an algorithmically generated author record based on publicly available information.

Hakan Uzunoglu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 May 2022
      • Vol. 93  (3) , 319-324

    Use of the Systemic Immune Inflammation Index, TNM classification, and CEA in pre- and post- prognostic evaluation of sporadic colorectal cancer

    by Hakan Uzunoglu, Mehmet Onur Gul, Umut Kina, Meryem Gunay Gurleyik

    Aim: The aim of this study was to investigate the correlation between preoperative systemic immune inflammatory index (SII) and carcinoembryonic antigen (CEA) and postoperative lympho-vascular invasion and TNM stage in patients with colorectal carcinoma. MATERIAL AND METHODS: A total of 153 patients with colorectal cancer admitted to our tertiary hospital between 2014 and 2018 were included in the study. RESULTS: While 71.2% of the patients had low preoperative CEA values, 28.8% had high preoperative CEA values. Lymphovascular invasion rate was found to be significantly higher in patients with high CEA levels than those in low levels (70.4% vs. 39.4%, p=0.002). The percentage of patients with lymphovascular invasion with a high SII (60.0%) was significantly higher than those without lymphovascular invasion (p=0.015). CONCLUSION: In our study, serum CEA and SII index values were found to provide critical information in terms of showing lympho-vascular invasion, which is considered as an independent "bad" prognostic factor in patients with colorectal carcinoma. In conclusion, we consider that CEA and SII index values can be used to determine the prognosis of patients with colorectal cancer.


  • Short-term Prognostic Value of Tumor Diameter in Stage 2 and 3 Gastric Cancer

    by Hakan Uzunoglu, Selcuk Kaya

    Objective: To investigate the prognostic value of tumor diameter in the short term of 3 and 5 years in patients operated for gastric cancer. Study Design: A descriptive study. Place and Duration of Study: Kartal Dr Lutfi Kirdar City Hospital, Istanbul, Turkey, from January 2014 to December 2018 Methodology: A total of 125 patients with stage 2 or 3 gastric cancer, followed up in the Department of General Surgery, were included. Demographic information, clinical, laboratory, and pathology reports were analysed in terms of postoperative 30-day mortality. Results: The mean age of the patients was 63.9 +/- 11.9 (31-88) years. Forty-four (35.2%) were in stage 2, and 81 (64.8%) were in stage 3 cancers. The mean tumor diameter was 6.5 +/- 3.1 cm, and the mean metastatic lymph node rate was 35.6 +/- 29.8%. The mean follow-up period was 31.8 +/- 21 months. The 3-year and 5-year survival rates were 39.8% and 17.6%, respectively. Tumor diameter was not directly related to survival, differentiation, number of resected lymph nodes, number of metastatic lymph nodes, and metastatic lymph node rate in stage 2 and 3 cases (p>0.05 for each). The 5-year mortality risk was 1.2-fold higher in those with tumor diameter over 6.5 cm (95% CI 0.7-2.0; p=536). Conclusion: The tumor size did not have a direct effect on prognosis. It did not provide reliable data about short-term prognosis such as 3 and 5 years in stage 2 and 3 gastric cancer cases.


  • Open Access

    Primary extra gastrointestinal stromal tumors of the abdomen

    by Hakan Uzunoglu, Yasin Tosun

    OBJECTIVE: In the present study, we aimed to evaluate the clinicopathological features and prognostic factors in extra-gastrointestinal stromal tumor (EGIST) cases, which are observed very rare, by examining the data the cases obtained in a single center. METHODS: Data of 14 EGIST cases who were operated by a general surgeon between January 2007 and May 2020 were obtained and analyzed. RESULTS: The median age was 47.5 (range: 34-87) years. A total of 135 patients were operated for GIST, and 14 (10.4%) of these patients were EGIST. The mean tumor diameter was 16.8 +/- 10.5 (range: 2.8-40) cm. The mitotic index was 5/50 high power field and below in seven (50%) cases. Twelve (85.7%) of the patients were in the high-risk group. The overall survival (OS) rate was 80%, and the 5-year survival rate was 88.9%. Mean OS was 78.5 +/- 50.7 months, 5-year OS and disease-free survival (DFS) were both 53.3 +/- 20.0 months, and overall DFS was 58.0 +/- 59.8 months. The mean OS and DFS durations were found to be significantly lower in women than men (p=0.006 for both comparisons). The mean OS was found to be significantly lower in patients over 60 years of age compared to those aged 60 and under (p=0.013). CONCLUSION: In the present study, it has been determined that the rare EGISTs are large in size and that the mitotic index is often low. In addition, it has been observed that the prognosis may be similar to other GISTs, however, may be worse in elderly patients and in women.